Maladie de Rendu-Osler (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Maladie de Rendu-Osler" in French language version.

refsWebsite

Global rank French rank

8nih.gov

4^th place

12^th place

6doi.org

2^nd place

3^rd place

2nejm.org

2,374^th place

298^th place

2sciencedirect.com

149^th place

80^th place

1nature.com

234^th place

147^th place

1utah.edu

2,446^th place

3,336^th place

1wiley.com

222^nd place

129^th place

1bmj.com

1,226^th place

347^th place

bmj.com

jmg.bmj.com

Faughnan ME, Palda VA, Garcia-Tsao G et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia, J Med Genet, 2011;48:73-87

doi.org

dx.doi.org

(en) Faughnan ME, Palda VA, Garcia-Tsao G. et al., « International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia », J Med Genet., vol. 48, n^o 2,‎ 2011, p. 73–87 (PMID 19553198, DOI 10.1136/jmg.2009.069013)
(en) Shovlin CL, « Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment », Blood Rev, vol. 24,‎ 2010, p. 203-19 (PMID 20870325, DOI 10.1016/j.blre.2010.07.001)
Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F, « Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output », JAMA, vol. 307,‎ 2012, p. 948-55 (PMID 22396517, DOI 10.1001/jama.2012.250)
D'Amato RJ, Loughnan MS, Flynn E, Folkman J, « Thalidomide is an inhibitor of angiogenesis », Proc Natl Acad Sci U S A, vol. 91,‎ 1994, p. 4082-5 (PMID 7513432, DOI 10.1073/pnas.91.9.4082)
(en) Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N, « Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation », Proc Natl Acad Sci USA, vol. 106,‎ 2009, p. 8573-8 (PMID 19433787, DOI 10.1073/pnas.0901505106)
(en) Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Bréant C, Mathivet T, Larrivée B, Thomas JL, Arthur HM, Westermann CJ, Disch F, Mager JJ, Snijder RJ, Eichmann A, Mummery CL, « Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia », Nat Med, vol. 16,‎ 2010, p. 420-8 (PMID 20364125, DOI 10.1038/nm.2131)

nature.com

Lesca G, Olivieri C, Burnichon N et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network, Genet Med, 2007,9:14-22

nejm.org

(en) McAllister KA, Grogg KM, Johnson DW et al. « Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 » Nat Genet. 1994;8:345-351
(en) Trembath RC, Thomson JR, Machado RD et al. « Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia » N Engl J Med. 2001;345:325-34.

nih.gov

ncbi.nlm.nih.gov

(en) Faughnan ME, Palda VA, Garcia-Tsao G. et al., « International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia », J Med Genet., vol. 48, n^o 2,‎ 2011, p. 73–87 (PMID 19553198, DOI 10.1136/jmg.2009.069013)
(en) Larson AM, « Liver disease in hereditary hemorrhagic telangiectasia » J Clin Gastroenterol. 2003;36:149-58.
(en) Shovlin CL, « Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment », Blood Rev, vol. 24,‎ 2010, p. 203-19 (PMID 20870325, DOI 10.1016/j.blre.2010.07.001)
Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F, « Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output », JAMA, vol. 307,‎ 2012, p. 948-55 (PMID 22396517, DOI 10.1001/jama.2012.250)
D'Amato RJ, Loughnan MS, Flynn E, Folkman J, « Thalidomide is an inhibitor of angiogenesis », Proc Natl Acad Sci U S A, vol. 91,‎ 1994, p. 4082-5 (PMID 7513432, DOI 10.1073/pnas.91.9.4082)
(en) Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N, « Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation », Proc Natl Acad Sci USA, vol. 106,‎ 2009, p. 8573-8 (PMID 19433787, DOI 10.1073/pnas.0901505106)
(en) Franchini M, Frattini F, Crestani S, Bonfanti C, « Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide », J Thromb Thrombolysis,‎ 2012 (PMID 23143669)
(en) Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Bréant C, Mathivet T, Larrivée B, Thomas JL, Arthur HM, Westermann CJ, Disch F, Mager JJ, Snijder RJ, Eichmann A, Mummery CL, « Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia », Nat Med, vol. 16,‎ 2010, p. 420-8 (PMID 20364125, DOI 10.1038/nm.2131)

sciencedirect.com

(en) Garcia-Tsao G, « Liver involvement in hereditary hemorrhagic telangiectasia (HHT) » J Hepatol. 2007;46:499-507.
(en) Ginon I, Decullier E, Finet G et al. « Hereditary hemorrhagic telangiectasia, liver vascular malformations and cardiac consequences » Eur J Intern Med. 2013;24:e35-e39.

utah.edu

arup.utah.edu

(en) HHT Mutation Database (Hereditary Hemorrhagic Telangiectasia)

wiley.com

onlinelibrary.wiley.com

(en) Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H, « Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome) » Am J Med Genet. 2000;91:66-7